Close Menu

NEW YORK (360Dx) – Opko Health today priced its public offering of $200 million in convertible senior notes.

The notes will be senior unsecured obligations of the company and pay interest semiannually in arrears at a rate of 4.5 percent per year. The notes , which will mature on Feb. 15, 2025, will be convertible into, at the company's decision, cash, shares of the company's common stock, or a combination of both.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.